| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal TA1005: Futibatinib for previously treated advanced cholangiocarcinoma with FGFR2 fusion or rearrangement |
|
Medicine details |
|
| Medicine name | futibatinib (Lytgobi®) |
| Formulation | 4 mg film-coated tablet |
| Reference number | 4998 |
| Indication | For previously treated advanced cholangiocarcinoma with FGFR2 fusion or rearrangement |
| Company | Taiho Pharma Netherlands B.V. |
| BNF chapter | Malignant disease & immunosuppression |
| Assessment type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 23/07/2024 |
| NICE guidance | |